On August 31, 2020 Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) reported six months data from its stability study with HyNap-Dasa tablets manufactured in commercial scale (Press release, Xspray, AUG 31, 2020, View Source [SID1234650108]). Six months stability data on commercially manufactured HyNap-Dasa demonstrates that the tablets complies with specifications and that they can be used in an upcoming ANDA filing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In February 2020 stability studies were initiated with HyNap-Dasa tablets manufactured in commercial scale according to GMP-standard. In accordance with regulatory requirements three batches were put on stability at accelerated conditions (40oC and 75% relative humidity) and normal conditions (25oC and 60% relative humidity). Xspray now announces that the six months data have been analyzed and show compliance with the specification.

"As expected, the stability study showed good results, which is necessary for the filing for market approval in the US. We continue to work intensively on the preparations to be able to file an application for market approval for HyNap-Dasa as soon as possible. In late September we are awaiting the results from the second bioequivalence study with HyNap-Dasa, thereafter we will decide on the best strategy for our upcoming ANDA filing," comments Per Andersson.